Literature DB >> 25543271

Valuing EQ-5D health states for Sri Lanka.

Sanjeewa Kularatna1, Jennifer A Whitty, Newell W Johnson, Ruwan Jayasinghe, Paul A Scuffham.   

Abstract

PURPOSE: The aim of this study was to derive an algorithm to estimate utility values for the EQ-5D-3L health states based on the preferences of a population sample from Sri Lanka.
METHODS: The time trade-off method was used to directly value 198 EQ-5D-3L health states in a general population sample (n = 780) from Sri Lanka. Stratified cluster sampling with random selection within clusters was used to select the sample from four districts. Each participant valued 15 health states via face-to-face interviews. The best fit model was selected using consistency, parsimony, and goodness of fit. Based on logical inconsistency, numerous sub-samples were also used for model specification. For each model, the numbers of illogical orderings in the resulting value set were also examined.
RESULTS: Generalised least squares with random effects were found to be the best specification. The sub-sample consisting of participants with less than seven logical inconsistent observations produced no illogical ordering in the final value set and is considered the preferred model. Compared to value sets in other countries, a high disutility is associated with level 3 deficits in the mobility dimension. More than 50 % of health states in the Sri Lankan value set are deemed worse than death health states.
CONCLUSIONS: Sri Lankan utility values for EQ-5D-3L states deviate markedly from existing values for upper middle and high-income countries. It is important to have country-specific utility values to conduct cost-utility analysis.

Entities:  

Mesh:

Year:  2014        PMID: 25543271     DOI: 10.1007/s11136-014-0906-2

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  13 in total

1.  A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states.

Authors:  X Badia; M Roset; M Herdman; P Kind
Journal:  Med Decis Making       Date:  2001 Jan-Feb       Impact factor: 2.583

2.  Estimating population-based values for EQ-5D health states in Thailand.

Authors:  Sirinart Tongsiri; John Cairns
Journal:  Value Health       Date:  2011-09-08       Impact factor: 5.725

Review 3.  Multi-attribute preference functions. Health Utilities Index.

Authors:  G W Torrance; W Furlong; D Feeny; M Boyle
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

Review 4.  International comparisons in valuing EQ-5D health states: a review and analysis.

Authors:  Richard Norman; Paula Cronin; Rosalie Viney; Madeleine King; Deborah Street; Julie Ratcliffe
Journal:  Value Health       Date:  2009-08-20       Impact factor: 5.725

5.  Inconsistency and health state valuations.

Authors:  P Dolan; P Kind
Journal:  Soc Sci Med       Date:  1996-02       Impact factor: 4.634

6.  A comparison of United States and United Kingdom EQ-5D health states valuations using a nonparametric Bayesian method.

Authors:  Samer A Kharroubi; Anthony O'Hagan; John E Brazier
Journal:  Stat Med       Date:  2010-07-10       Impact factor: 2.373

7.  Time trade-off derived EQ-5D weights for Australia.

Authors:  Rosalie Viney; Richard Norman; Madeleine T King; Paula Cronin; Deborah J Street; Stephanie Knox; Julie Ratcliffe
Journal:  Value Health       Date:  2011-08-04       Impact factor: 5.725

8.  Modeling valuations for EuroQol health states.

Authors:  P Dolan
Journal:  Med Care       Date:  1997-11       Impact factor: 2.983

9.  Argentine valuation of the EQ-5D health states.

Authors:  Federico Ariel Augustovski; Vilma Edit Irazola; Alberto Pascual Velazquez; Luz Gibbons; Benjamin M Craig
Journal:  Value Health       Date:  2008-11-12       Impact factor: 5.725

10.  Study protocol for valuing EQ-5D-3L and EORTC-8D health states in a representative population sample in Sri Lanka.

Authors:  Sanjeewa Kularatna; Jennifer A Whitty; Newell W Johnson; Paul A Scuffham
Journal:  Health Qual Life Outcomes       Date:  2013-09-02       Impact factor: 3.186

View more
  7 in total

1.  Cost-effectiveness analysis of telephone-based support for the management of pressure ulcers in people with spinal cord injury in India and Bangladesh.

Authors:  M Arora; L A Harvey; J V Glinsky; H S Chhabra; M S Hossain; N Arumugam; P K Bedi; I D Cameron; A J Hayes
Journal:  Spinal Cord       Date:  2017-08-15       Impact factor: 2.772

2.  Comparison of the EQ-5D-3L and the SF-6D (SF-12) contemporaneous utility scores in patients with cardiovascular disease.

Authors:  Sanjeewa Kularatna; Joshua Byrnes; Yih Kai Chan; Chantal F Ski; Melinda Carrington; David Thompson; Simon Stewart; Paul A Scuffham
Journal:  Qual Life Res       Date:  2017-08-01       Impact factor: 4.147

3.  Development of a preference-based heart disease-specific health state classification system using MacNew heart disease-related quality of life instrument.

Authors:  Sanjeewa Kularatna; Donna Rowen; Clara Mukuria; Steven McPhail; Gang Chen; Brendan Mulhern; Jennifer A Whitty; Joshua Byrnes; Paul Scuffham; John Atherton; Stefan Höfer; William Parsonage
Journal:  Qual Life Res       Date:  2021-05-26       Impact factor: 4.147

4.  Evaluation of a self-help intervention to promote the health and wellbeing of marginalised people including those living with leprosy in Nepal: a prospective, observational, cluster-based, cohort study with controls.

Authors:  Dilip Shrestha; Indra B Napit; Subi Ansari; Sopna Mannan Choudhury; Bishnu Dhungana; Paramjit Gill; Frances Griffiths; Holly Gwyther; Deanna Hagge; Shovakhar Kandel; Suraj Puri; Jo Sartori; Samuel Ian Watson; Richard Lilford
Journal:  BMC Public Health       Date:  2021-05-06       Impact factor: 3.295

5.  Logical inconsistencies in time trade-off valuation of EQ-5D-5L health states: Whose fault is it?

Authors:  Zhihao Yang; Jan van Busschbach; Reinier Timman; M F Janssen; Nan Luo
Journal:  PLoS One       Date:  2017-09-21       Impact factor: 3.240

6.  Comparison of the EQ-5D 3L and the SF-6D (SF-36) contemporaneous utility scores in patients with chronic kidney disease in Sri Lanka: a cross-sectional survey.

Authors:  Sanjeewa Kularatna; Sameera Senanayake; Nalika Gunawardena; Nicholas Graves
Journal:  BMJ Open       Date:  2019-02-15       Impact factor: 2.692

7.  An individual randomised efficacy trial of autologous blood products, leukocyte and platelet-rich fibrin (L-PRF), to promote ulcer healing in leprosy in Nepal: the TABLE trial protocol.

Authors:  Indra B Napit; Dilip Shrestha; Jon Bishop; Sopna Choudhury; Santosh Dulal; Paramjit Gill; Eleni Gkini; Holly Gwyther; Deanna A Hagge; Karuna Neupane; Jo Sartori; Gemma Slinn; Samuel I Watson; Richard Lilford
Journal:  Trials       Date:  2021-07-15       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.